FDA News Release – Multiple Sclerosis

Angie Szumlinski Announcements, News

On March 26, 2021, the U.S. Food and Drug Administration authorized the marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older.

“MS is one of the most common neurological diseases in young adults. Today’s authorization offers a valuable new aid in physical therapy and increases the value of additional therapies for those who live with MS on a daily basis”, said Christopher M. Loftus, M.D., acting director of the Office of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health.

There are so many reasons that this device could bring much-needed relief to patients living with MS. Imagine the freedom of movement, needing less assistive devices, enjoying the “normal” things in life like going for a walk! Obviously, more research will be done and patients should only use the device after seeking professional medical advice but wow, what a great breakthrough! Stay well, mask up and stay tuned!